Search Results 1-10 of 15450 for %EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BDKA%EF%BF%BD%EF%BF%BD%EF%BF%BD%3AZA31%EF%BF%BD%EF%BF%BD%EF%BF%BD24%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%20%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD
The purpose of this study is to assess the effectiveness of the Low EF AI-ECG and encompassing software for detecting LVEF ≤ 40% by echocardiography, compared ...
Sponsor Protocol Number: EF-25 METIS. About this study. The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and ...
... EF). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns ...
Title: EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of OPTUNE® (TTFields, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the ...
... EF (BEAT HFpEF): A Randomized Controlled Trial (BEAT HFpEF) Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With ...
Low EF aortic stenosis (EF<50%); Multivalvular heart disease (>moderate or previous prosthetic valve); Active ischemia (unstable angina, myocardial infarction ...
C. Cancer Biology and Translational Research: John A. Copland III · Cancer Research and Cellular Therapies: Januario E. Castro · Cardiovascular Disease and ...
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products ...
Participation eligibility · Non-responder Patients: EF measured with BiV ON; · Previously Untreatable Patients: EF measured with CS Lead OFF (if it exists), or in ...
... EF-27 (PANOVA-3)) Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.